Case Control Study
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastroenterol. Jul 28, 2014; 20(28): 9534-9540
Published online Jul 28, 2014. doi: 10.3748/wjg.v20.i28.9534
Figure 1
Open in New Tab Full Size Figure Download Figure
Figure 1 Flow chart of enrolled patients. IBD: Inflammatory bowel disease; pt: Patients; BPs: Bisphosphonates; DMT2: Diabetes mellitus type 2; PPI: Proton pump inhibitors; OGTT: Oral glucose tolerance test; IGT: Impaired glucose tolerance.
Figure 2
Open in New Tab Full Size Figure Download Figure
Figure 2 Baseline levels of serum C-terminal crosslinking telopeptide of type I collagen in controls and in patients with Crohn’s disease active or in remission. CTX: C-terminal crosslinking telopeptide of type I collagen; CD: Crohn’s disease. aP < 0.05 vs control group.
Figure 3
Open in New Tab Full Size Figure Download Figure
Figure 3 The effect of oral glucose load in serum C-terminal crosslinking telopeptide of type I collagen levels in patients with Crohn’s disease and in the control group. CTX: C-terminal crosslinking telopeptide of type I collagen; CD: Crohn’s disease. aP < 0.05 vs baseline values.
Figure 4
Open in New Tab Full Size Figure Download Figure
Figure 4 %suppression of serum C-terminal crosslinking telopeptide of type I collagen levels at 2 h after oral glucose load in controls and in patients with Crohn’s disease active or in remission. aP < 0.05 vs control group; cP < 0.05 vs patients with active Crohn’s disease (CD). CTX: C-terminal crosslinking telopeptide of type I collagen.